4.31

8.10% -0.38

After Hours: 4.30 -0.010 -0.23%

Trisalus Life Sciences Inc (TLSI)

Overview News Price History Discussions Forecast

Trisalus Life Sciences Inc stock is traded at $4.31, with a volume of 246.16K. It is down -8.10% in the last 24 hours and up +35.96% over the past month. TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Previous Close:

$4.69

Open:

$4.69

24h Volume:

246.16K

Relative Volume:

0.56

Market Cap:

$264.71M

Revenue:

$45.15M

Net Income/Loss:

$-39.23M

P/E Ratio:

-2.3565

EPS:

-1.829

Net Cash Flow:

$-18.93M

1W Performance:

-9.07%

1M Performance:

+35.96%

6M Performance:

-26.83%

1Y Performance:

-14.99%

1-Day Range:

$4.27

$4.70

1-Week Range:

$4.27

$4.76

52-Week Range:

$2.20

$7.95

Trisalus Life Sciences Inc Stock (TLSI) Company Profile

Name

Trisalus Life Sciences Inc

Sector

Healthcare (1100)

Industry

Medical Devices (142)

Phone

415 336 8917

Address

6272 WEST 91ST AVENUE, WESTMINSTER

Employee

102

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

TLSI's Discussions on Twitter

Compare TLSI vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TLSI Trisalus Life Sciences Inc	4.31	279.45M	45.15M	-39.23M	-18.93M	-1.829
ABT Abbott Laboratories	95.63	158.05B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	324.73	120.70B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.06	100.14B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.60	63.44B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	95.18	52.09B	6.30B	1.07B	1.09B	1.8406

Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
Nov-11-24	Initiated	ROTH MKM	Buy
Oct-25-24	Initiated	Northland Capital	Outperform
Sep-16-24	Initiated	Oppenheimer	Outperform
May-30-24	Initiated	Canaccord Genuity	Buy

View All

Trisalus Life Sciences Inc Stock (TLSI) Latest News

Jul 01, 2026

TriSalus (TLSI) CEO Mary Szela acquires 3,990 ESPP shares, now holds 1.08M - Stock Titan

Jul 01, 2026

TriSalus Life Sciences (TLSI) CCO acquires 561 ESPP shares - Stock Titan

Jul 01, 2026

Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView

Jul 01, 2026

Jun 29, 2026

Form 4 TriSalus Life Sciences Inc For: 29 June By Investing.com - Investing.com Canada

Jun 29, 2026

TriSalus Life Sciences (TLSI) CMO awarded RSUs and 120,000-share option grant - Stock Titan

Jun 29, 2026

TriSalus (TLSI) CMO discloses common stock and option holdings in Form 3 - Stock Titan

Jun 29, 2026

TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026

TriSalus Life Sciences, Inc. Actuals & Estimates (NASDAQ:TLSI) - TradingView

Jun 26, 2026

Jun 25, 2026

TLSI Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Canaccord reiterates TriSalus stock Buy rating after KOL event - Investing.com UK

Jun 25, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc.TLSI - PR Newswire

Jun 25, 2026

CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Jun 25, 2026

Canaccord reiterates TriSalus stock Buy rating after KOL event By Investing.com - Investing.com UK

Jun 25, 2026

Jun 24, 2026

TriSalus Life Sciences (TLSI) Gains 3.23% as Shares Test Resistance at $4.37Ichimoku Kumo Twist - dars.gov.et

Jun 24, 2026

Jun 21, 2026